Research map: Optimised mesalazine therapy reduces ulcerative colitis recurrence across the mild-to-moderate disease spectrum: the IMPACT study

Back to the article

Papers in this map

  1. Ulcerative colitis · Taku Kobayashi · 2020 · 1674 citations · Cited by this paper
  2. A case report of adult congenital intestinal malrotation · 2025 · Related
  3. Ulcerative colitis · Catherine Le Berre · 2023 · 1617 citations · Cited by this paper
  4. The challenging diagnosis of sinistral portal hypertension in a patient with liver cirrhosis: a case report and literature review · 2026 · Related
  5. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment · Tim Raine · 2021 · 1107 citations · Cited by this paper
  6. Efficacy and safety of trastuzumab deruxtecan in gastrointestinal malignancies: a systemic review and meta-analysis · 2025 · Related
  7. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study · Philippe R. Marteau · 2005 · 365 citations · Cited by this paper
  8. Malaria and malnutrition in tribal areas of India: implications for paediatric health · 2025 · Related
  9. Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis · Michael A. Kamm · 2006 · 353 citations · Cited by this paper
  10. Helicobacter pylori infection in gastric cancer patients in French Guiana: a hospital-based study (2018–2023) · 2026 · Related
  11. Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial · Stephen B. Hanauer · 2007 · 165 citations · Cited by this paper
  12. MASH and the race for liver antifibrotics · 2026 · Related
  13. Oral versus combination mesalazine therapy in active ulcerative colitis: a double‐blind, double‐dummy, randomized multicentre study · Maurizio Li Vecchi · 2001 · 90 citations · Cited by this paper
  14. Case Report: jaundice in the young: the complexity of rare diseases beyond cholangiopathies · 2025 · Related
  15. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing - ASCEND I and II combined analysis · Gary R. Lichtenstein · 2011 · 88 citations · Cited by this paper
  16. New-onset diabetes as an emerging risk group for early detection of pancreatic cancer: current evidence, clinical challenge, and future directions · 2026 · Related
  17. The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine · Giuseppe Frieri · 2017 · 35 citations · Cited by this paper
  18. Ischemic proctitis caused by a superior rectal arteriovenous fistula: a case report and literature review · 2026 · Related
  19. Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis · Kristine Paridaens · 2021 · 25 citations · Cited by this paper
  20. Recent advances, comparative performance, and data requirements of artificial intelligence-assisted technologies for the diagnosis of gastric cancer · 2026 · Related
  21. Efficacy of Long-Term 4.0 g/Day Mesalazine (Pentasa) for Maintenance Therapy in Ulcerative Colitis · Kazuhiko Nakao · 2014 · 18 citations · Cited by this paper
  22. Mesalazine granules promote disease clearance in patients with mild‐to‐moderate ulcerative colitis · Wolfgang Kruis · 2023 · 18 citations · Cited by this paper
  23. Practical management of mild-to-moderate ulcerative colitis: an international expert consensus · Ferdinando D’Amico · 2024 · 16 citations · Cited by this paper
  24. Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study · Mary Kaye Willian · 2018 · 12 citations · Cited by this paper
  25. Lower Risk of Recurrence with a Higher Induction Dose of Mesalazine and Longer Duration of Treatment in Ulcerative Colitis: Results from the Dutch, Non-Interventional, IMPACT Study · Rachel Louise West · 2022 · 11 citations · Cited by this paper
  26. Real-world evidence of quality of life improvement in patients with distal ulcerative colitis treated by mesalazine: the Quartz study · Thierry Paupard · 2022 · 7 citations · Cited by this paper
  27. Shared decision-making improves adherence to mesalamine in ulcerative colitis: A prospective, multicenter, non-interventional cohort study in Germany · Wolfgang Kruis · 2025 · 6 citations · Cited by this paper
  28. P142 Ulcerative colitis: risk factors for relapse in clinical remission patients · Cátia Arieira · 2019 · 1 citation · Cited by this paper
  29. Untitled · Cited by this paper

Source: OpenAlex (CC0)